
-
ADC Therapeutics NYSE:ADCT ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Location: BiopOle, Epalinges, 1066, Switzerland | Website: https://www.adctherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
561.6M
Cash
194.7M
Avg Qtr Burn
-34.02M
Short % of Float
5.47%
Insider Ownership
21.36%
Institutional Own.
59.68%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Follicular lymphoma, Mantle cell lymphoma, Diffuse large B cell lymphoma | Approved Update | |
Camidanlumab Tesirine (CD25) Details Solid tumor/s, Cancer, Hodgkin Lymphoma | BLA Submission | |
ZYNLONTA (Loncastuximab Tesirine) + rituximab Details Diffuse large B cell lymphoma | Phase 3 Data readout | |
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Cancer, Blood cancer, Marginal zone lymphoma | Phase 2 Data readout | |
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Cancer, Blood cancer, Diffuse large B cell lymphoma | Phase 2 Update | |
ZYNLONTA + Rituximab Details Blood cancer, Follicular lymphoma | Phase 2 Update | |
ZYNLONTA (Loncastuximab Tesirine) + COLUMVI (glofitamab) Details Diffuse large B-cell lymphoma (DLBCL) | Phase 1b Data readout | |
ADCT-602 (CD22) Details Acute lymphoblastic leukemia | Phase 1a Data readout | |
Mipasetamab Uzoptirine (ADCT-601) (AXL) Details Solid tumor/s, Cancer | Failed Discontinued | |
ADCT-901 (targeting KAAG1) Details Solid tumor/s, Cancer | Failed Discontinued | |
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details Cancer, Diffuse large B cell lymphoma | Failed Discontinued |